Developer docs
API playgroundTry for free, no card

Search company profiles

aceso therapeutics

Full company profile

uuid02molyh

Namestring
aceso therapeutics
Legal namestring
Aceso Therapeutics
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Aceso Therapeutics is a preclinical-stage French biotech developing molecular therapies for cystic fibrosis (CF), headquartered in Montpellier, France and founded in 2022 by Thomas Tran (CEO), Magali Taulan-Cadars (CSO), and Prisca Boisguerin (CTO). The company originates from over a decade of academic research at Montpellier-based institutions (CNRS, INSERM, Université de Montpellier) and focuses on the approximately 20% of the 162,000+ CF patients worldwide who are underserved by existing CFTR modulators due to genotype constraints, partial efficacy, or prohibitive treatment costs exceeding $300K per patient per year.

The company's core technology is the PTGR (Post-Transcriptional Gene Restoration) platform, a proprietary system that restores gene expression by masking microRNA binding sites in the 3'UTR region of mRNA, protected by three international patent families (ASO-TBS filed 2013; Peptide WRAP filed 2018). The lead asset ACT-101 is a first-in-class inhaled antisense oligonucleotide (ASO) that stabilizes CFTR mRNA, with up to 60% CFTR functional activity restoration demonstrated in primary patient-derived bronchial epithelial (ALI) models across F508del homozygous and compound heterozygous genotypes. The pipeline extends to ACT-201 (CFTR protein stabilizer), ACT-301 (ACT-101/ACT-201 bitherapy), ACT-401 (splicing defect corrector), ACT-102 (nonsense mutation therapy), WRAP-1 (cell-penetrating peptide delivery vector), and ACT-105 (COPD anti-inflammatory). ACT-101 targets a Clinical Trial Application (CTA) submission in late 2027, with clinical development in 2028 and an efficacy endpoint targeted for 2031.

Aceso operates a pre-commercial, partnership-driven business model with no current revenue. Capital sources to date include a €500K SATT grant (2020), an ANR grant (2023), the Bpifrance i-Lab Innovation Competition award (2026), and an equity investment by technology transfer office SATT AxLR in March 2026; the company is also raising approximately €1.5M (partially secured) to complete regulatory preclinical studies. Development partners include WuXi (CMC), Aptar Pharma / Nanopharm (formulation and Orbital dry powder inhaler device), ILIFE (clinical study design), L2D (regulatory strategy), the Cystic Fibrosis Foundation, and Bpifrance. The company attends industry partnering events (BIO International Convention, ECFS conferences, Deeptech Connect) and pursues eventual monetization through licensing, co-development, or independent commercialization with major pharma partners.

Short descriptiontext

Aceso Therapeutics is a preclinical French biotech developing first-in-class inhaled antisense oligonucleotide therapies for cystic fibrosis via its proprietary PTGR platform, targeting CF patients underserved by current CFTR modulators, with lead asset ACT-101 advancing toward a 2027 CTA submission.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMontpellier, France
HQ citystring
Montpellier
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cystic fibrosis therapeutics, antisense oligonucleotide therapy, CFTR gene restoration, respiratory drug development, preclinical biotech pipeline
Industry4 codes
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Cystic Fibrosis Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-revenue / Development Stage
TypeLicensing Royalties
Description

Aceso Therapeutics is a pre-commercial biotech company in preclinical development stage. No revenue currently generated. The company is funded through grants, investor capital, and partnership contributions to advance ACT-101 and pipeline programs toward clinical development and eventual commercialization through licensing, co-development, or independent commercialization.

aceso-therapeutics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Aceso Therapeutics is a preclinical-stage biotech company developing molecular therapies for cystic fibrosis (CF) and respiratory conditions. Its proprietary PTGR (Post-Transcriptional Gene Restoration) platform produces first-in-class antisense oligonucleotide (ASO) and peptide therapeutics, with lead candidate ACT-101 being an inhaled ASO that stabilizes CFTR mRNA to increase CFTR protein production in CF patients with Class II mutations. The company pursues partnerships with pharmaceutical developers, CROs, and academic institutions to advance candidates toward CTA submission targeted for 2027.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 60% CFTR functional activity restoration in patient-derived bronchial epithelial models
+3 more records
Product overview1 text field

Aceso Therapeutics is a biotech company operating a unified therapeutic platform called PTGR (Post-Transcriptional Gene Restoration) focused on cystic fibrosis. The core product is ACT-101, a first-in-class inhaled antisense oligonucleotide (ASO) that stabilizes CFTR mRNA. Supporting programs include ACT-201 (CFTR protein stabilizer), ACT-301 (bitherapy combining ACT-101 and ACT-201), ACT-401 (splicing defect corrector), ACT-102 (nonsense mutation therapy), WRAP-1 (cell-penetrating peptide delivery vector), and ACT-105 (COPD program). The pipeline addresses multiple CFTR mutation classes and disease indications, with ACT-101 as the most clinically advanced lead candidate targeting CTA submission in 2027.

Product and service6 records
1ACT-101
CategoryCystic Fibrosis Therapeutic Candidate
Description

First-in-class inhaled antisense oligonucleotide (ASO) designed for cystic fibrosis patients with Class II (F508del) mutations. ACT-101 stabilizes CFTR mRNA to increase CFTR protein production, offered as a potential standalone or combination therapy with existing CFTR modulators. Demonstrated up to 60% CFTR functional activity restoration in patient-derived bronchial epithelial models.

2ACT-201
CategoryCystic Fibrosis Therapeutic Candidate
Description

CFTR protein stabilization therapeutic program using a novel peptide to increase stability and half-life of mutated CFTR protein at the apical membrane. Targets cystic fibrosis patients with Class II (F508del) mutations.

3ACT-301
CategoryCystic Fibrosis Therapeutic Candidate
Description

Bitherapy combining ACT-101 and ACT-201 for synergistic CFTR rescue, restoring both CFTR expression and protein stability for improved efficacy in cystic fibrosis patients with Class II mutations.

4ACT-401
CategoryCystic Fibrosis Therapeutic Candidate
Description

RNA splicing defect therapeutic program targeting CF Class I mutations, designed to correct splicing defects in CFTR pre-mRNA.

5ACT-102
CategoryCystic Fibrosis Therapeutic Candidate
Description

Nonsense mutation therapeutic program targeting CF Class I mutations, designed to address nonsense mutations in the CFTR gene.

6ACT-105
CategoryRespiratory Therapeutic Candidate
Description

Anti-inflammatory therapeutic program targeting COPD (Chronic Obstructive Pulmonary Disease), focused on addressing inflammatory mechanisms associated with CFTR-related pathways.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-09-07
Description

Collaboration to advance ACT-101, an inhaled antisense oligonucleotide for cystic fibrosis. Aptar's Nanopharm business leads formulation development and device assessment to support the candidate's clinical advancement. Follows earlier partnership between Aptar and Aceso. Partnership leverages Aptar's Orbital dry powder inhaler technology and inhalation services expertise.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Research collaboration since December 2025 with Université de Montpellier and PhyMedExp laboratories for development of new therapeutic approaches for cystic fibrosis. PhyMedExp focuses on cardiovascular, muscle, and respiratory research from basic science to clinical applications. Collaboration includes INSERM and CNRS expertise.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration with WuXi to accelerate and secure ACT-101's CMC (Chemistry, Manufacturing and Controls) development. Leverages WuXi's recognized global expertise and comprehensive capabilities in pharmaceutical development.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration with ILIFE to anticipate the design of ACT-101's clinical study synopsis and secure next development stage by leveraging recognized clinical expertise of ILIFE's team.

5L2D
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Collaboration with L2D to advance ACT-101's regulatory development efficiently and securely, supported by recognized regulatory expertise.

aceso-therapeutics.com
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

French national institute for health and medical research. Key research partner with joint units including PhyMedExp for CFTR biology research.

7CNRS
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

French National Centre for Scientific Research. Key academic research partner in CFTR biology and therapeutic development with joint laboratory affiliations.

aceso-therapeutics.com
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic partner in CF research collaboration contributing to the scientific foundation of the platform.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

University Hospital of Lille - clinical collaboration partner in cystic fibrosis research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Dutch RNA therapeutics company developing antisense oligonucleotides (e.g., eluforsen) for cystic fibrosis and other rare genetic diseases; directly comparable in modality (ASOs), indication space (CF), and patient population (CFTR mutation classes underserved by modulators).

TypeDirect peer
Description

Israeli biotech developing inhaled antisense oligonucleotides for cystic fibrosis, targeting splicing defects in CFTR — extremely close comparator in technology platform (inhaled ASO), indication (CF), and clinical positioning (mutation-class-specific).

TypeBroad incumbent
Description

Global leader in cystic fibrosis therapeutics with Trikafta/Kaftrio franchise; sets the standard of care and competitive benchmark for any new CF therapy addressing F508del and other mutation classes.

TypeDirect peer
Description

Clinical-stage RNA therapeutics company with a stereopure antisense oligonucleotide platform targeting genetic diseases; comparable in ASO modality, rare-disease focus, and platform-based discovery approach.

TypeBroad incumbent
Description

Pioneer and established leader in antisense oligonucleotide drug discovery and development; comparable in ASO modality and rare disease focus, with broader neurology and cardiometabolic pipeline providing incumbency context.

TypeBroad incumbent
Description

Leading RNA therapeutics company (siRNA platform) with approved drugs and rare-disease focus; comparable as a broad incumbent RNA modality player that competes for partnership and capital in the same RNA therapeutics ecosystem.

TypeEmerging player
Description

Emerging biotech developing gene therapies for cystic fibrosis; comparable as another modality-based entrant targeting the same underserved CF population, though using AAV gene delivery instead of ASOs.

TypeEmerging player
Description

Clinical-stage genetic medicines company with a CFTR gene therapy program for cystic fibrosis; comparable as an emerging CF therapeutic developer pursuing novel mechanisms for patients underserved by existing modulators.

9Translate Bio
TypeEmerging player
Description

mRNA therapeutics developer (acquired by Sanofi) that previously advanced an inhaled mRNA program for cystic fibrosis; comparable as another RNA-modality competitor targeting pulmonary CFTR delivery in the same patient segment.

TypeEmerging player
Description

Clinical-stage RNA medicines company developing mRNA and siRNA therapeutics with proprietary lipid nanoparticle delivery; comparable as an emerging RNA therapeutics player with pulmonary and rare disease ambitions.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

aceso therapeutics

Cystic Fibrosis Therapeuticsaceso-therapeutics.com

Aceso Therapeutics is a preclinical French biotech developing first-in-class inhaled antisense oligonucleotide therapies for cystic fibrosis via its proprietary PTGR platform, targeting CF patients underserved by current CFTR modulators, with lead asset ACT-101 advancing toward a 2027 CTA submission.

What aceso therapeutics does

Aceso Therapeutics is a preclinical-stage French biotech developing molecular therapies for cystic fibrosis (CF), headquartered in Montpellier, France and founded in 2022 by Thomas Tran (CEO), Magali Taulan-Cadars (CSO), and Prisca Boisguerin (CTO). The company originates from over a decade of academic research at Montpellier-based institutions (CNRS, INSERM, Université de Montpellier) and focuses on the approximately 20% of the 162,000+ CF patients worldwide who are underserved by existing CFTR modulators due to genotype constraints, partial efficacy, or prohibitive treatment costs exceeding $300K per patient per year.

The company's core technology is the PTGR (Post-Transcriptional Gene Restoration) platform, a proprietary system that restores gene expression by masking microRNA binding sites in the 3'UTR region of mRNA, protected by three international patent families (ASO-TBS filed 2013; Peptide WRAP filed 2018). The lead asset ACT-101 is a first-in-class inhaled antisense oligonucleotide (ASO) that stabilizes CFTR mRNA, with up to 60% CFTR functional activity restoration demonstrated in primary patient-derived bronchial epithelial (ALI) models across F508del homozygous and compound heterozygous genotypes. The pipeline extends to ACT-201 (CFTR protein stabilizer), ACT-301 (ACT-101/ACT-201 bitherapy), ACT-401 (splicing defect corrector), ACT-102 (nonsense mutation therapy), WRAP-1 (cell-penetrating peptide delivery vector), and ACT-105 (COPD anti-inflammatory). ACT-101 targets a Clinical Trial Application (CTA) submission in late 2027, with clinical development in 2028 and an efficacy endpoint targeted for 2031.

Aceso operates a pre-commercial, partnership-driven business model with no current revenue. Capital sources to date include a €500K SATT grant (2020), an ANR grant (2023), the Bpifrance i-Lab Innovation Competition award (2026), and an equity investment by technology transfer office SATT AxLR in March 2026; the company is also raising approximately €1.5M (partially secured) to complete regulatory preclinical studies. Development partners include WuXi (CMC), Aptar Pharma / Nanopharm (formulation and Orbital dry powder inhaler device), ILIFE (clinical study design), L2D (regulatory strategy), the Cystic Fibrosis Foundation, and Bpifrance. The company attends industry partnering events (BIO International Convention, ECFS conferences, Deeptech Connect) and pursues eventual monetization through licensing, co-development, or independent commercialization with major pharma partners.

aceso therapeutics firmographics

Firmographics
Name
aceso therapeutics
Legal name
Aceso Therapeutics
Website
https://aceso-therapeutics.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
Aceso Therapeutics is a preclinical French biotech developing first-in-class inhaled antisense oligonucleotide therapies for cystic fibrosis via its proprietary PTGR platform, targeting CF patients underserved by current CFTR modulators, with lead asset ACT-101 advancing toward a 2027 CTA submission.
Ownership category
akta.pro rank

aceso therapeutics industry classification

Industry
Product category
Cystic Fibrosis Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAC
Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Cystic fibrosis therapeutics
  • Antisense oligonucleotide therapy
  • CFTR gene restoration
  • Respiratory drug development
  • Preclinical biotech pipeline

Where aceso therapeutics is headquartered

Location

Headquarters

HQ city
Montpellier
HQ country
France
HQ region
Europe

Offices1 record

Markets served

aceso therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Pre-revenue / Development Stage: Aceso Therapeutics is a pre-commercial biotech company in preclinical development stage. No revenue currently generated. The company is funded through grants, investor capital, and partnership contributions to advance ACT-101 and pipeline programs toward clinical development and eventual commercialization through licensing, co-development, or independent commercialization.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

aceso therapeutics product offering

Product offering

Core offering

Aceso Therapeutics is a preclinical-stage biotech company developing molecular therapies for cystic fibrosis (CF) and respiratory conditions. Its proprietary PTGR (Post-Transcriptional Gene Restoration) platform produces first-in-class antisense oligonucleotide (ASO) and peptide therapeutics, with lead candidate ACT-101 being an inhaled ASO that stabilizes CFTR mRNA to increase CFTR protein production in CF patients with Class II mutations. The company pursues partnerships with pharmaceutical developers, CROs, and academic institutions to advance candidates toward CTA submission targeted for 2027.

Product overview

Aceso Therapeutics is a biotech company operating a unified therapeutic platform called PTGR (Post-Transcriptional Gene Restoration) focused on cystic fibrosis. The core product is ACT-101, a first-in-class inhaled antisense oligonucleotide (ASO) that stabilizes CFTR mRNA. Supporting programs include ACT-201 (CFTR protein stabilizer), ACT-301 (bitherapy combining ACT-101 and ACT-201), ACT-401 (splicing defect corrector), ACT-102 (nonsense mutation therapy), WRAP-1 (cell-penetrating peptide delivery vector), and ACT-105 (COPD program). The pipeline addresses multiple CFTR mutation classes and disease indications, with ACT-101 as the most clinically advanced lead candidate targeting CTA submission in 2027.

Differentiator

Problem solved

Functional benefit

Products and services

  • ACT-101 First-in-class inhaled antisense oligonucleotide (ASO) designed for cystic fibrosis patients with Class II (F508del) mutations. ACT-101 stabilizes CFTR mRNA to increase CFTR protein production, offered as a potential standalone or combination therapy with existing CFTR modulators. Demonstrated up to 60% CFTR functional activity restoration in patient-derived bronchial epithelial models.
  • ACT-201 CFTR protein stabilization therapeutic program using a novel peptide to increase stability and half-life of mutated CFTR protein at the apical membrane. Targets cystic fibrosis patients with Class II (F508del) mutations.
  • ACT-301 Bitherapy combining ACT-101 and ACT-201 for synergistic CFTR rescue, restoring both CFTR expression and protein stability for improved efficacy in cystic fibrosis patients with Class II mutations.
  • ACT-401 RNA splicing defect therapeutic program targeting CF Class I mutations, designed to correct splicing defects in CFTR pre-mRNA.
  • ACT-102 Nonsense mutation therapeutic program targeting CF Class I mutations, designed to address nonsense mutations in the CFTR gene.
  • ACT-105 Anti-inflammatory therapeutic program targeting COPD (Chronic Obstructive Pulmonary Disease), focused on addressing inflammatory mechanisms associated with CFTR-related pathways.

Quantifiable outcome

  • 60% CFTR functional activity restoration in patient-derived bronchial epithelial models
  • +3 more outcomes

Companies that use aceso therapeutics

Customer profile

Segments2 records

Ideal customer profiles3 records

aceso therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

aceso therapeutics partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, major and supporting.

  • Aptar Pharma (Nanopharm)coreTechnology or Integration · 7 September 2026Collaboration to advance ACT-101, an inhaled antisense oligonucleotide for cystic fibrosis. Aptar's Nanopharm business leads formulation development and device assessment to support the candidate's clinical advancement. Follows earlier partnership between Aptar and Aceso. Partnership leverages Aptar's Orbital dry powder inhaler technology and inhalation services expertise.
  • Université de Montpellier / PhyMedExpcoreStrategic or Co-development Partner · 1 December 2025Research collaboration since December 2025 with Université de Montpellier and PhyMedExp laboratories for development of new therapeutic approaches for cystic fibrosis. PhyMedExp focuses on cardiovascular, muscle, and respiratory research from basic science to clinical applications. Collaboration includes INSERM and CNRS expertise.
  • WuXimajorStrategic or Co-development PartnerCollaboration with WuXi to accelerate and secure ACT-101's CMC (Chemistry, Manufacturing and Controls) development. Leverages WuXi's recognized global expertise and comprehensive capabilities in pharmaceutical development.
  • ILIFEmajorStrategic or Co-development PartnerCollaboration with ILIFE to anticipate the design of ACT-101's clinical study synopsis and secure next development stage by leveraging recognized clinical expertise of ILIFE's team.
  • L2DmajorStrategic or Co-development PartnerCollaboration with L2D to advance ACT-101's regulatory development efficiently and securely, supported by recognized regulatory expertise.
  • INSERMsupportingStrategic or Co-development PartnerFrench national institute for health and medical research. Key research partner with joint units including PhyMedExp for CFTR biology research.
  • CNRSsupportingStrategic or Co-development PartnerFrench National Centre for Scientific Research. Key academic research partner in CFTR biology and therapeutic development with joint laboratory affiliations.
  • Université de LillesupportingStrategic or Co-development PartnerAcademic partner in CF research collaboration contributing to the scientific foundation of the platform.
  • CHU LillesupportingStrategic or Co-development PartnerUniversity Hospital of Lille - clinical collaboration partner in cystic fibrosis research.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

aceso therapeutics competitors and assessment

Company assessment

Direct peers

  • ProQR Therapeutics: Dutch RNA therapeutics company developing antisense oligonucleotides (e.g., eluforsen) for cystic fibrosis and other rare genetic diseases; directly comparable in modality (ASOs), indication space (CF), and patient population (CFTR mutation classes underserved by modulators).
  • SpliSense: Israeli biotech developing inhaled antisense oligonucleotides for cystic fibrosis, targeting splicing defects in CFTR — extremely close comparator in technology platform (inhaled ASO), indication (CF), and clinical positioning (mutation-class-specific).
  • Wave Life Sciences: Clinical-stage RNA therapeutics company with a stereopure antisense oligonucleotide platform targeting genetic diseases; comparable in ASO modality, rare-disease focus, and platform-based discovery approach.

Broad incumbents

  • Vertex Pharmaceuticals: Global leader in cystic fibrosis therapeutics with Trikafta/Kaftrio franchise; sets the standard of care and competitive benchmark for any new CF therapy addressing F508del and other mutation classes.
  • Ionis Pharmaceuticals: Pioneer and established leader in antisense oligonucleotide drug discovery and development; comparable in ASO modality and rare disease focus, with broader neurology and cardiometabolic pipeline providing incumbency context.
  • Alnylam Pharmaceuticals: Leading RNA therapeutics company (siRNA platform) with approved drugs and rare-disease focus; comparable as a broad incumbent RNA modality player that competes for partnership and capital in the same RNA therapeutics ecosystem.

Emerging players

  • Spirovant Sciences: Emerging biotech developing gene therapies for cystic fibrosis; comparable as another modality-based entrant targeting the same underserved CF population, though using AAV gene delivery instead of ASOs.
  • 4D Molecular Therapeutics: Clinical-stage genetic medicines company with a CFTR gene therapy program for cystic fibrosis; comparable as an emerging CF therapeutic developer pursuing novel mechanisms for patients underserved by existing modulators.
  • Translate Bio: mRNA therapeutics developer (acquired by Sanofi) that previously advanced an inhaled mRNA program for cystic fibrosis; comparable as another RNA-modality competitor targeting pulmonary CFTR delivery in the same patient segment.
  • Arcturus Therapeutics: Clinical-stage RNA medicines company developing mRNA and siRNA therapeutics with proprietary lipid nanoparticle delivery; comparable as an emerging RNA therapeutics player with pulmonary and rare disease ambitions.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

aceso therapeutics social profiles

Digital presence

aceso therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

aceso therapeutics leadership team

Management profile

Number of profiles

Profiles4 records

aceso therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

aceso therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about aceso therapeutics

What does aceso therapeutics do?

Aceso Therapeutics is a preclinical-stage biotech company developing molecular therapies for cystic fibrosis (CF) and respiratory conditions. Its proprietary PTGR (Post-Transcriptional Gene Restoration) platform produces first-in-class antisense oligonucleotide (ASO) and peptide therapeutics, with lead candidate ACT-101 being an inhaled ASO that stabilizes CFTR mRNA to increase CFTR protein production in CF patients with Class II mutations. The company pursues partnerships with pharmaceutical developers, CROs, and academic institutions to advance candidates toward CTA submission targeted for 2027.

Is aceso therapeutics a public or private company?

aceso therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was aceso therapeutics founded?

aceso therapeutics was founded in 2022. It employs 1 to 10 people.

Where is aceso therapeutics based?

aceso therapeutics is headquartered in Montpellier, France, in the Europe region.

How does aceso therapeutics make money?

One revenue line is on record: pre-revenue / Development Stage.

Who are aceso therapeutics's main competitors?

Direct peers on record are ProQR Therapeutics, SpliSense and Wave Life Sciences. Broad incumbents are Vertex Pharmaceuticals, Ionis Pharmaceuticals and Alnylam Pharmaceuticals. Emerging players are Spirovant Sciences, 4D Molecular Therapeutics, Translate Bio and Arcturus Therapeutics.

Does aceso therapeutics have an API?

No public API is recorded for aceso therapeutics.

What industry is aceso therapeutics in?

aceso therapeutics's product category is Cystic Fibrosis Therapeutics. Its primary akta.pro industry code is HLAAADAC, Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown), with a secondary code of HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals